A randomised controlled trial of three or one breathing technique training sessions for breathlessness in people with malignant lung disease by Johnson, Miriam J et al.
Johnson et al. BMC Medicine  (2015) 13:213 
DOI 10.1186/s12916-015-0453-xRESEARCH ARTICLE Open AccessA randomised controlled trial of three or
one breathing technique training sessions
for breathlessness in people with malignant
lung disease
Miriam J Johnson1*, Mona Kanaan2, Gerry Richardson3, Samantha Nabb4, David Torgerson2, Anne English5,6,
Rachael Barton7 and Sara Booth8,9Abstract
Background: About 90 % of patients with intra-thoracic malignancy experience breathlessness. Breathing training is
helpful, but it is unknown whether repeated sessions are needed. The present study aims to test whether three
sessions are better than one for breathlessness in this population.
Methods: This is a multi-centre randomised controlled non-blinded parallel arm trial. Participants were allocated to
three sessions or single (1:2 ratio) using central computer-generated block randomisation by an independent Trials
Unit and stratified for centre. The setting was respiratory, oncology or palliative care clinics at eight UK centres.
Inclusion criteria were people with intrathoracic cancer and refractory breathlessness, expected prognosis ≥3
months, and no prior experience of breathing training. The trial intervention was a complex breathlessness
intervention (breathing training, anxiety management, relaxation, pacing, and prioritisation) delivered over three
hour-long sessions at weekly intervals, or during a single hour-long session. The main primary outcome was worst
breathlessness over the previous 24 hours (‘worst’), by numerical rating scale (0 = none; 10 = worst imaginable).
Our primary analysis was area under the curve (AUC) ‘worst’ from baseline to 4 weeks. All analyses were by
intention to treat.
Results: Between April 2011 and October 2013, 156 consenting participants were randomised (52 three; 104 single).
Overall, the ‘worst’ score reduced from 6.81 (SD, 1.89) to 5.84 (2.39). Primary analysis [n = 124 (79 %)], showed no
between-arm difference in the AUC: three sessions 22.86 (7.12) vs single session 22.58 (7.10); P value = 0.83); mean
difference 0.2, 95 % CIs (–2.31 to 2.97). Complete case analysis showed a non-significant reduction in QALYs with
three sessions (mean difference –0.006, 95 % CIs –0.018 to 0.006). Sensitivity analyses found similar results. The
probability of the single session being cost-effective (threshold value of £20,000 per QALY) was over 80 %.
Conclusions: There was no evidence that three sessions conferred additional benefits, including cost-effectiveness,
over one. A single session of breathing training seems appropriate and minimises patient burden.
Trial registration: Registry: ISRCTN; Trial registration number: ISRCTN49387307; http://www.isrctn.com/ISRCTN49387307;
registration date: 25/01/2011
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Lung cancer is the most common cause of death
from cancer worldwide, responsible for an estimated
one in five (1.59 million deaths, 19.4 % total deaths)
[1]. Rarely curable, breathlessness is a problem in up
to 90 % of patients [2]. Breathlessness is harder to
treat than pain and is a cause of emergency hospital
admission [3, 4]. Complex non-pharmacological sup-
portive care interventions for people with lung cancer
appear to be beneficial and cost-effective, although
which intervention components are the most benefi-
cial is less clear [5–11]. Four phase III trials have
compared a complex breathlessness intervention with
standard care [7, 9–11], two using intensity of breath-
lessness as the primary outcome [7, 9], one using the
mastery subscale of the Chronic Respiratory Ques-
tionnaire (CRQ) [11], and one using patient distress
due to breathlessness (numerical rating scale (NRS)
0–10) [10]. All trials demonstrated clinically and sta-
tistically significant benefit with the intervention.
The National Institute for Health and Clinical Ex-
cellence (NICE) guidance for Lung Cancer recom-
mends access to these treatments [12], although there
is a need for further research regarding optimum ser-
vice delivery, particularly for cancer patients where
the evidence base is less strong than for rehabilitation
programmes in non-malignant cardiorespiratory con-
ditions [13, 14]. A review of exercise-based training
for people with non-small cell lung cancer concluded
that there was some benefit for exercise tolerance
(often limited by breathlessness), but these studies fo-
cussed on people having surgery, rather than those
living with lung cancer [15].
The systematic implementation of breathing training
services for people with cancer in practice is challen-
ging [16]. Visits to or by clinicians may be onerous to
patients with a poor performance status and progres-
sive disease, such as those with lung cancer, even if
provided in their own home. However, many patients
have no training at all or receive a single ad hoc ses-
sion only; it is unknown whether such single sessions
are effective.
The primary hypothesis was that three sessions are su-
perior to one, in terms of worst breathlessness intensity
over the previous 24 hours in people with intrathoracic
cancer. The primary objective was to assess the effective-
ness of these two modes of delivery with regard to the
relief of breathlessness intensity. We anticipated that
three sessions of breathing training would have greater
benefit than one.
Secondary objectives were to test which mode was
more effective for other aspects of breathlessness, func-
tion, quality of life, psychological distress and coping,
and cost-effectiveness.Methods
Trial design
This multi-centre pragmatic randomised controlled non-
blinded parallel arm trial assessed the effect of breathing
training delivered over three 1 hour-long sessions at
weekly intervals, or during a single session in the man-
agement of patients with refractory breathlessness due
to intrathoracic cancer.
Participants and setting
Patients from eight centres in England, Scotland, and
Wales attending hospital respiratory, oncology, pallia-
tive care clinics or hospices were screened by the re-
search nurse in conjunction with the patients’ usual
clinical team. Adults with intra-thoracic malignancy
(primary or secondary tumours) were eligible. Partici-
pants could be randomised to trial intervention if they
had refractory breathlessness with a self-reported inten-
sity of ≥3/10 on a NRS, where 0 = no breathlessness and
10 = worst imaginable breathlessness, and a clinician-
estimated prognosis of at least 3 months. Participants
with breathlessness intensity of <3/10 were followed-up
at monthly intervals to assess eligibility for randomisa-
tion. Refractory breathlessness was defined as persistent
breathlessness despite treatment of reversible causes
[17]. Patients were excluded if they had intercurrent ill-
ness or co-morbidities making completion of the trial
unlikely, worsening breathlessness requiring urgent
medical intervention, or prior breathing training.
Centres were eligible if clinicians provided breathing
training and were willing to deliver the trial intervention.
The intervention could be delivered in the hospital, hos-
pice, or a patient’s home according to patient choice.
The protocol, procedures, and trial documentation
were approved by the independent UK Integrated
Research Approval System via the Sheffield Research
Ethics Committee (ref 10/H1308/66). Subsequent
Research and Development NHS governance approval
was obtained for all sites prior to recruitment. The trial
was registered (ISRCTN49387307) and the protocol
followed CONSORT recommendations. All participants
gave written informed consent.Intervention and comparator
All participants received training in four techniques
(Box 1) during an hour-long session, supported by
written and DVD/video reinforcement material and a
telephone call from their therapist a week after the
last session. Those randomised to the three session
arm received two further hour-long clinic sessions at
weeks 2 and 3 to reinforce and practice the tech-
niques. Training was provided by the usual therapist
providing the service.
Box 1. Breathing management techniques
Breathing control
The patient sits comfortably with their back supported, the
shoulders relaxed, and the upper chest remaining as still as
possible. The patient places their hand in front of the lower ribs
and upper abdomen, and is asked to breathe in and then out,
taking longer than the time taken to breathe in.
Pacing/prioritising
The patient is taught to control their breathing when walking up
stairs or on level ground. They are instructed to breathe in time with
the steps taken, e.g. breathe in for one step and then breathe out for
two. The patient is instructed to find the rhythm that suits them best.
Participants define their priorities regarding daily activity which
is limited by dyspnoea. Goals are set, and a plan discussed with
the therapist on how they may be achieved.
Relaxation
The patient is instructed in progressive muscle relaxation using a
standard script and given a study-specific CD to practise at home.
Anxiety management
Patients are instructed to use a tool called The Calming Hand
[39]. Patients are asked to recall instructions when they
experience anxiety or panic. Each instruction is related to a digit
on their hand: thumb, recognise breathing related anxiety; index
finger, sigh out; third finger, inhale slowly; fourth finger, exhale
slowly; little finger, relax hands, stretch and stop.
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dardised prior to trial commencement, but different cen-
tres could provide local additional non-pharmacological
therapies such as exercise if this was a usual part of their
service. The type of professional (e.g. nurse, physiotherap-
ist, occupational therapist) was not stipulated.Outcomes
The primary outcome measure, defined by previous
feasibility work [18], was patient-reported intensity of
the worst breathlessness over the past 24 hours (‘worst’;
0–10 numerical rating scale [NRS], 0 = no breathless-
ness; 10 = the worst imaginable breathlessness) [19, 20].
Secondary measures included average intensity of
breathlessness over the past 24 hours (‘average’); distress
due to breathlessness and 0–10 NRS coping with breath-
lessness (‘distress’) using NRS 0–10 scales anchored with
0 = none and 10 = worst; ‘coping’ and satisfaction with
care of breathlessness (using 0–10 NRS scales anchored
with 0 = none and 10 = best outcome); injustice andcatastrophizing scale; quality of life Chronic Respiratory
Questionnaire - Self-Administered-Survey (CRQ-SAS)
[21]; Hospital Anxiety and Depression Scale (HADS) [22];
Karnofsky performance scale (KPS), [23], health status
(EQ-5D and EQ-visual analogue scale (EQVAS)) [24]; cop-
ing (BriefCOPE) [25]; and global impression of change
and health service utilisation.
Baseline assessments included demographic data (age, sex,
smoking history), KPS, medication and personality aspects
(Big Five Inventory (BFI) [26]; Mental Toughness Question-
naire (MTQ)), and pre-randomisation preference for trial
allocation. Follow-up assessments were at weeks 1, 2, 3, 4,
and 8 after the first training session. All outcome measures
were assessed at baseline, week 4, and week 8 except the Big
Five Inventory and Mental Toughness Questionnaire. At
weeks 1–3 only NRS scores, EQ-5D and EQVAS were mea-
sured. Adverse events were noted at each contact. The
primary analysis point was week 4. After week 8 participants
had an optional monthly telephone call from the trial nurse
to record NRS intensity until withdrawal or death.
Sample size
Using data from previous feasibility work [18] to detect
a difference of 30 % in area under the curve (AUC) for
NRS worst breathlessness (standard deviation (SD), 2.6)
at 4 weeks at 80 % power and 5 % two-tailed statistical
significance, with a 2:1 randomisation, allowing for 30 %
attrition, a sample size of 146 participants was needed. Al-
though week 4 attrition in the feasibility trial was 50 %, a
reduction to 30 % was anticipated with earlier consent
(consent to trial participation even if their reported
breathlessness intensity did not fulfil the criteria for ran-
domisation). AUC was chosen as more indicative of the
experience of breathlessness over the trial than change in
NRS scores, or comparison of week 4 NRS scores as it in-
cludes measures at weekly time points.
Sample size re-calculation
A review of week 4 attrition (June 2013) showed nearly
30 % drop out. In order to reduce the risk of loss of
power, a further 10 participants were recruited.
Randomisation and masking
Online 3- or 6-block randomisation (central computer
generated sequence) and allocation of consenting partici-
pants was performed by the York Trials Unit using a 1:2
ratio (1 three: 2 single). This was done in order to minim-
ise a potential increase in demand on usual services from
participating in a trial actively seeking to recruit patients.
As this was a pragmatic trial, centres maintained their
usual practice other than providing the intervention stand-
ard components. To account for site differences in cancer
therapies and additional breathlessness measures, partici-
pants were stratified by centre. Initially, stratification for
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as this would not always be known at randomisation, this
was not done. Due to the likelihood of participants inad-
vertently disclosing their allocation arm to the research
nurse, allocation was not blinded [18]. Trial assessments
were conducted by research nurses.
Statistical methods
Baseline characteristics are described and presented in
tabular form for all participants and presented by
whether they were lost to follow-up or remained in the
trial. Mean and SD are presented for quantitative data
and number and percentage for categorical data. Sum-
mary statistics over time are also reported for the re-
peated outcome measures as are missing data.
For the primary analysis of AUC at 4 weeks (worst
breathlessness), we used a two-sample t-test to compare
the two arms. Multiple regression was used to estimate
the effect of three sessions compared to one adjusting for
baseline characteristics (age, sex, baseline breathlessness
intensity, and smoking status). To account for missing
data we i) utilised multiple imputation method for the pri-
mary outcome and ii) used complete cases for all second-
ary measures. Variation resulting from different practices
at different sites was accounted for in the analysis by the
stratification [27]. Management of missing data for the
cost-effectiveness analysis is described below.
Cost-effectiveness analysis
The cost-effectiveness of three sessions versus one was com-
pared. Costs were estimated for both arms and included the
cost of the intervention and other health-related resource
use costs. The effectiveness measure for this analysis was
the Quality Adjusted Life Year (QALY) generated from re-
sponses to the EQ5D. A sensitivity analysis using multiple
imputation to account for missing data was performed.
Results
Between April 2011 and October 2013, 156 participants
were randomised (52 to three sessions; 104 to single ses-
sion). Two withdrew from each arm prior to the inter-
vention and were excluded from the analysis. Data for
the AUC from baseline to week 4 for the primary out-
come was available for 124 (79 %) participants. Partici-
pant flow throughout the trial, including reasons for
withdrawal, can be seen in Fig. 1.
Trial setting and implementation
In this pragmatic trial, the intervention was delivered in
a variety of settings and by different therapists (Table 1).
All four techniques were documented in the clinical rec-
ord. In the single arm, 91 (89 %) received one session of
all four techniques. In the three session arm, 39 (78 %)
received three sessions of all the techniques.Trial population
Baseline characteristics between the two arms were
similar apart from a clinically important difference in
the mastery domain of the CRQ-SAS (three 3.9 [SD,
1.18]; single 4.48 [1.17]) and anxiety (HADS three
7.62 [4.34]; single 6.12 [4.19]; Table 2). For the group
as a whole, the average age was 69.4 [9.35] years and
40 % were women. ‘Worst’ and ‘average’ breathless-
ness intensity was 6.81 [1.89] and 5.53 [1.68], respect-
ively; 133 (88.6 %) had a primary lung carcinoma, 12
(8 %) had mesothelioma, and 5 (3.3 %) had an extra-
thoracic primary site. Lung metastases were present in 23
(17 %). The average KPS was 70.6 % [9.54]. Most were ex-
smokers (114 [76 %]) or current smokers (23 [15 %]).
Baseline measures were similar for pre-randomisation
preference for trial allocation, mood, personality, or cop-
ing approaches, which might have influenced engagement
with the intervention.
Primary outcome
Overall, the ‘worst’ score reduced from 6.81 (SD, 1.89) at
baseline to 5.84 (2.39) at week 4. There was no between-
arm difference in the AUC (cubic): three sessions 22.86
(7.12) versus single session 22.58 (7.10); P value = 0.83;
mean difference 0.2, 95 % CIs (−2.31 to 2.97).
Secondary outcomes
There was no evidence of a between-arm difference in
the AUC for ‘average’ and ‘coping’ although both arms
improved by week 4 for all domains of the CRQ-SAS.
However, in the three session arm, both distress from
breathlessness (AUC 16.23 [7.17] three vs 12.29 [8.27]
single; P = 0.01) and sense of mastery over breathless-
ness (4.44 [1.25] three vs 5.03 [1.15] single; P = 0.02)
were worse.
Adjusting for baseline variables (Table 3), baseline
breathlessness intensity strongly predicted the AUC;
greater with worse baseline breathlessness (P = 0.001). A
consistent pattern, although not statistically significant,
was seen for current smoker status: associated with
worse AUC for ‘worst’ (co-efficient 4.06; 95 % –1.36 to
9.49), ‘average’ (4.67; 0.11 to 9.24), ‘distress’ (5.13; –0.75
to 11.0), ‘coping’ (–5.11; CIs –10.7 to 0.53), and ‘satisfac-
tion’ (–7.66; –14 to –1.35) compared with never
smokers; these estimates were higher than those associ-
ated with ex-smoker status (‘worst’ 3.15, –0.43 to 7.74;
‘average’ 2.82, –1.08 to 6.73; ‘distress’ 2.98, –1.95 to 7.91;
‘cope’ –4.84, –9.64 to –0.04; ‘satisfaction’ –5.17, –10.4 to
0.04) compared to never smokers. Descriptive statistics
for the summary weekly measures at weeks 4 and 8 are
shown in Table 4. Outcomes relating to perception of or
response to breathlessness/general condition show a
consistent pattern of improvement over time, although
less so for the fatigue domain of the CRQ-SAS.
Fig. 1 CONSORT 2010 flow diagram
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Complete case analysis showed a small non-significant re-
duction in overall QALYs with three sessions (mean differ-
ence –0.006, 95 % CIs –0.018 to 0.006). These results
were confirmed in a sensitivity analysis using multiple im-
putation of data (mean difference in QALYs –0.008, 95 %
CI –0.022 to 0.006). Complete case analysis also showed a
small non-significant increase in costs associated with
three sessions. Thus, the single session would be consid-
ered dominant (improved outcomes at lower cost). The
probability of the single session being cost-effective at a
threshold value of £20,000 per QALY was over 80 %.
There was no evidence that the additional cost of three
sessions is offset by lower resource use elsewhere and
three sessions is associated with a worse QALY profile.
Therefore, the single session intervention is likely to be
cost-effective.
Sensitivity analyses
The sensitivity analyses using complete cases for second-
ary outcomes did not show any material difference.Likewise, the analysis using multiple imputation for the
primary outcome measure failed to demonstrate any
significant difference.
A post hoc sensitivity analysis was performed in view
of the clinically significant difference in baseline CRQ
mastery domain and HADS anxiety in order to adjust
for this difference, but did not materially affect the
results (Additional file 1).
Harms
Overall, 50/156 (32 %) participants experienced 58 serious
adverse events (deaths (30) or hospitalisation (28)). All were
unrelated to the intervention and were expected events in
the context of progressive cancer/comorbidities, apart from
two (one in each allocated arm) which were unrelated to
the intervention, but were unexpected (a fractured neck of
femur following a fall and a femoral artery embolus).
Discussion
There was a clinically significant improvement, equating
to a moderate effect [28], in breathlessness intensity and
Table 1 Implementation of intervention in centres
Centre/Site principal investigator Setting Breathing training provided by Recruited
Cambridge University NHS
Hospitals Foundation Trust
Hospital Physiotherapist or Occupational Therapist: specialist
palliative care breathlessness intervention service
12
Dr Sara Booth
NHS Wales Cardiff and Vale University
Health Board and Velindre NHS Trust
Tertiary oncology service
and palliative care clinics
Physiotherapist 24
Dr Anthony Byrne
University Hospitals Coventry
and Warwickshire NHS Trust
Cancer centre oncology clinics Lung cancer clinical nurse specialists 15
Dr Alison Franks
East Kent University Hospitals NHS Trust Hospice units Physiotherapist 28
Dr Andrew Thorns
NHS Lothian Oncology and palliative care clinics Physiotherapist 2
Prof Marie Fallon
NHS Greater Glasgow and Clyde Tertiary lung cancer clinic Physiotherapist 25
Dr Noelle O’Rourke
Hull and East Yorkshire Hospitals NHS
Trust and Dove House Hospice, Hull
Tertiary oncology service and
breathlessness intervention service
Physiotherapist: hospital and hospice based
specialist palliative care breathlessness
intervention service
33
Dr Rachael Barton
Dartford and Gravesham NHS Trust Hospice units and district general
hospital oncology clinics
Physiotherapist 17
Dr Burhan Khan
156
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consistent with the benefit identified in usual care con-
trolled trials [7, 9–11]. However, there was no evidence
that three sessions conferred greater benefit than a sin-
gle session for any of the outcomes. Furthermore, al-
though not statistically significant, there was a greater
reduction in health status in the three session arm com-
pared with those receiving only one.
In both arms, improvements relating to the perception
of breathlessness and response to living with it (intensity
of breathlessness, distress due to, coping with and satisfac-
tion of care of breathlessness; dyspnoea and mastery
CRQ-SAS, anxiety, depression, sense of injustice and cata-
strophizing) were seen. This is consistent with the model
of breathlessness as having two recognisable components,
namely perception and emotional response [29], which
can be reported by the patient [30] and has a physiological
basis demonstrable by neuroimaging [31]. Measures which
are more likely to represent underlying pathological pro-
cesses such as the fatigue domain and KPS, either im-
proved very little or deteriorated.
The prognosis for lung cancer remains poor for those
unsuitable for surgery or other radical treatment and
breathlessness is a feature of advanced rather than early
stage cancer [32]. In our trial, participants were required
to have at least moderate breathlessness (>3/10 NRS) to
be randomised. Although the average performance statusat baseline was 71 %, 30 (19 %) had died and 14 (8 %)
were too unwell to provide data by 4 weeks, consistent
with breathlessness as a sign of poor outcome.
The burden of unmet psychological and daily living
needs in people with lung cancer is high [33], leading to
calls for attention to palliative care needs, in the light of
effective interventions [34] and evidence that palliative
care reduces inappropriate and costly healthcare inter-
ventions [35]. A trial of early palliative care involvement
in people with non-small cell lung cancer demonstrated
improvement in quality of life and mood in conjunction
with improved survival and less aggressive care at the
end of life [36]. Two recently reported ‘fast track’ trials,
which included breathlessness management interven-
tions, confirmed benefit for those randomised to early
rather than late palliative care [10, 11].
The economic and clinical burden of lung cancer
treatment has been highlighted [37], but less is known
about the burden of palliative care. The burden of non-
pharmacological interventions should not be assumed to
be negligible for people with advancing disease although
reported patient and carer experience suggests that a
comprehensive complex intervention is valued [10, 11].
However, just as the optimum dose of cancer treatment
is assessed for net-benefit, so palliative care interven-
tions should be given the same consideration. It is of
concern that distress due to breathlessness was rated
Table 2 Baseline characteristics
All participants Participants lost Remaining participants
Variable Three sessions Single session Total Three Single Three Single
N 52 104 156 9 23 43 81
Withdrew at baseline 2 2 4
Age in years:
mean (SD [MS] 68 (11) [0] 69 (9) [1] 69 (9) [1] 67 (8) [0] 68 (8) [1] 69 (11) [0] 70 (9) [0]
min, max 38, 87 47, 92 38, 92 53, 77 55, 83 38, 87 47, 92
Sex: N (%) [MS]
Female 21 (43) [1] 39 (39) [2] 60 (40) [3] 1 (11) [0] 6 (29) [2] 21 (50) [1] 33 (41) [0]
Intrathoracic tumour: N (%) [0 MS] [2 MS] [2 MS] [0 MS] [2 MS] [0 MS] [0 MS]
Non-small cell 14 (28) 21 (21) 35 (23.3) 4 (44) 5 (24) 11 (26) 17 (21)
Small cell 1 (2) 4 (4) 5 (3.3) 2 (9) 1 (2) 2 (2)
Lung (histology not stated) 30 (60) 63 (63) 93 (62) 5(56) 13 (62) 26 (60) 51 (63)
Mesothelioma 4 (8) 8 (8) 12 (8) 1 (5) 4 (9) 7 (9)
Other 1 (2) 4 (4) 5 (3.3) 1 (2) 4 (5)
Metastases: N (%) [MS]
Yes 9 (19) [2] 14 (16) [12] 23 (17) [14] 1 (14) [2] 5 (29) [6] 8 (19) [1] 9 (12) [6]
Preference: N (%) [0 MS] [1 MS] [1 MS] [0 MS] [1 MS] [0 MS] [0 MS]
High 14 (28) 20 (20) 34 (22.5) 1 (11) 3 (14) 13 (30) 17 (21)
Low 8 (16) 26 (26) 34 (22.5) 3 (33) 5 (23) 6 (14) 22 (27)
No preference 28 (56) 55 (54) 83 (55) 5 (56) 14 (64) 24 (56) 42 (52)
Smoking: N (%) [0 MS] [2 MS] [2 MS] [1 MS] [1 MS] [0 MS] [1 MS]
Never 6 (12) 7 (7) 13 (9) 6 (14) 7 (9)
Current 7 (14) 16 (16) 23 (15) 2 (25) 3 (14) 5 (12) 13 (16)
Ex-smoker 37 (74) 77 (77) 114 (76) 6 (75) 19 (86) 32 (74) 60 (75)
Karnofsky
Mean (SD) [MS] 70.6 (9.0) [3] 70.6 (9.9) [7] 70.6 (9.5) [10] 62.5 (8.9) [1] 63.8 (13.2) [2] 71.7 (8.6) [2] 72.2 (7.9) [5]
Breathlessness scores NRS:
mean (SD) [MS]
Worst 6.7 (2.0) [6] 6.9 (1.9) [12] 6.8 (1.9) [18] 7.6 (1.8) [1] 7.4 (1.8) [3] 6.6 (2.0) [6] 6.7 (1.9) [10]
Average 5.4 (1.8) [6] 5.6 (1.6) [13] 5.5 (1.7) [19] 6.0 (1.3) [1] 6.6 (2.0) [3] 5.3 (1.9) [6] 5.3 (1.4) [11]
Distress 4.7 (2.8) [7] 4.6 (3.1) [12] 4.6 (3.0) [19] 4.5 (2.3) [1] 5.7 (3.0) [3] 4.7 (2.8) [7] 4.3 (3.1) [10]
Cope 6.4 (2.1) [6] 7.0 (2.1) [12] 6.8 (2.1) [18] 6.3 (2.4) [1] 6.3 (2.1) [3] 6.5 (2.0) [6] 7.2 (2.1) [10]
Care provided 6.3 (3.4) [9] 6.5 (3.4) [20] 6.5 (3.4) [29] 5.6 (2.8) [2] 6.0 (3.6) [4] 6.3 (3.6) [8] 6.8 (3.3) [17]
Chronic Respiratory Questionnaire –
SAS: mean (SD) [MS]
Dyspnoea domain 4.41 (1.25) [0] 4.38 (1.31) [1] 4.39 (1.30) [1] 3.95 (1.32) [1] 4.38 (1.43) [1] 4.50 (1.22) [0] 4.38 (1.27) [0]
Fatigue 3.02 (0.95) [0] 3.32 (1.11) [2] 3.22 (1.07) [2] 2.72 (0.81) [1] 2.94 (1.14) [2] 3.06 (0.97) [0] 3.41 (1.08) [0]
Emotional function 4.17 (1.10) [0] 4.50 (1.28) [2] 4.39 (1.23) [2] 3.54 (1.12) [1] 3.81 (1.38) [2] 4.26 (1.09) [0] 4.68 (1.17) [0]
Mastery 3.90 (1.19) [0] 4.48 (1.17) [2] 4.2 9 (1.20) [2] 2.94 (0.50) [1] 3.78 (1.35) [2] 4.06 (1.19) [0] 4.66 (1.03) [0]
Hospital Anxiety and Depression
Scale (HADS): mean (SD) [MS]
Anxiety 7.6 (4.3) [0] 6.1 (4.4) [4] 6.6 (4.3) [4] 8.5 (4.8) [1] 8.4 (5.0) [3] 7.6 (4.3) [0] 5.6 (3.7) [1]
Depression 6.6 (3.0) [0] 6.2 (3.9) [2] 6.3 (3.6) [2] 8.1 (2.2) [1] 7.9 (4.9) [2] 6.4 (3.1) [0] 5.8 (3.5) [0]
Big Five Inventory (BFI): [MS] mean (SD) [0] [4] [4] [1] [4] [0] [1]
Extraversion 3.06 (0.75) 3.30 (0.83) 3.22 (0.81) 3.11 (0.94) 3.00 (0.78) 3.05 (0.71) 3.37 (0.82)
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Table 2 Baseline characteristics (Continued)
Agreeableness 4.22 (0.53) 4.16 (0.64) 4.18 (0.60) 3.96 (0.65) 3.99 (0.91) 4.26 (0.49) 4.20 (0.55)
Conscientiousness 4.00 (0.64) 4.11 (0.61) 4.07 (0.62) 3.90 (0.60) 3.94 (0.69) 4.00 (0.66) 4.16 (0.59)
Neuroticism 2.64 (0.83) 2.51 (0.88) 2.55 (0.86) 3.01 (0.89) 2.93 (1.08) 2.60 (0.82) 2.40 (0.80)
Openness 3.32 (0.75) 3.30 (0.70) 3.31 (0.71) 3.09 (0.81) 3.11 (0.81) 3.34 (0.75) 3.34 (0.67)
Mental Toughness Questionnaire
(MTQ48): [MS] mean (SD)
[1] [4] [5] [3] [5] [0] [0]
Challenge 3.7 (0.7) 3.8 (0.7) 3.78 (0.7) 3.7 (0.7) 3.7 (0.8) 3.7 (0.7) 3.8 (0.6)
Commitment 3.6 (0.7) 3.8 (0.6) 3.7 (0.6) 3.5 (0.7) 3.5 (0.8) 3.6 (0.7) 3.8 (0.6)
Control emotion 3.3 (0.6) 3.3 (0.6) 3.3 (0.6) 3.3 (0.4) 3.1 (0.8) 3.25 (0.7) 3.3 (0.6)
Control life 3.6 (0.7) 3.7 (0.7) 3.7 (0.7) 3.7 (0.9) 3.5 (0.8) 3.59 (0.7) 3.77 (0.6)
Confidence abilities 3.6 (0.6) 3.7 (0.6) 3.7 (0.6) 3.7 (0.5) 3.5 (0.8) 3.6 (0.6) 3.68 (0.6)
Confidence interpersonal 3.72 (0.82) 3.84 (0.75) 3.80 (0.77) 4.12 (0.99) 3.83 (0.66) 3.67 (0.79) 3.83 (0.78)
Pre-randomisation patient
stated preference for study
allocation: [MS] N (%)
[0] [1] [1] [0] [1] [0] [0]
Three sessions 14 (28) 20 (20) 34 (22.5) 1 (11) 3 (14) 13 (30) 17 (21)
Single session 8 (16) 26 (26) 34 (22.5) 3 (33) 5 (23) 6 (14) 22 (27)
No preference 28 (56) 55 (54) 83 (55) 5 (56) 14 (64) 24 (56) 42 (52)
**Adjusted for baseline breathlessness intensity, gender, smoking status, and age; Descriptive statistics of the primary and secondary breathlessness outcome
measures, P values and unadjusted and adjusted confidence intervals for the difference between the two arms
N = number SAS, Self-administered survey (supported by research nurse); SD, Standard deviation; AUC, Area under the curve. MS = Missing
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to note that those who withdrew from the trial had a
lower performance status. If patients are taught how to
address their breathlessness themselves in a single ses-
sion and then allowed to see how they manage without
repeat visits (with their inherent logistic challenges for
those who are unwell to get to a clinic, or arrange their
day to accommodate a clinician to visit) then this may
be increasing self-efficacy, reducing logistic challenges
related to health service contact and thus reducing dis-
tress. In this clinical context of ongoing deterioration
due to intra-thoracic cancer, our data do not support
more than one session of supervised breathing training.
Strengths and limitations
In keeping with our research question, we did not have a
‘usual care’ control arm and cannot show the trajectory
of outcome variables without any breathing intervention.
We did not attempt to blind trial allocation from the re-
search team. Others have attempted assessor blinding;
advertent or inadvertent disclosure occurred in about
half [10].
We have no objective measure of physical activity (e.g.
walk test), aiming to maximize trial data completion
with the most clinically relevant answers to the question,
whilst minimizing participant burden. Repeat measures
of performance and health status give a measure of
everyday activity. Likewise, we made the decision not to
document physiological measures of respiratory functionsuch as peak expiratory flow rate or other comorbidities.
By the time a patient with lung cancer becomes moder-
ately or severely breathless, their prognosis is poor and
symptom management is of paramount importance.
Therefore, in order to focus on the most patient-relevant
outcome, our primary outcome was patient-reported
breathlessness, with other measures of breathlessness
and performance status as secondary outcomes, rather
than surrogate pathophysiological biomarkers. Both peak
flow rate and the 6-minute walk test correlate poorly
with quality of life and breathlessness in this complex
setting [38]. Likewise, we have described our population
(those who have had the treatment for their cancer and
any other co-morbidities causing breathlessness opti-
mized; refractory breathlessness) by symptom intensity
and performance status rather than with co-morbidities.
Potential participants with medical problems or comor-
bidities considered sufficient to affect trial completion
were excluded. Eligibility criteria also required that iden-
tified reversible causes of breathlessness were treated
prior to trial entry if appropriate to do so, in the opinion
of the attending clinician.
Generalizability
The pragmatic nature of this trial is a major strength. It in-
volved a variety of settings, centres, and clinicians across
the UK. The results should therefore be generalizable
across a wide range of service settings and delivery
models. Furthermore, there are few trials of supportive
Table 3 Primary analysis point (4 weeks)
Variable Three sessions One session Total P-Value† 95% Confidence Interval Adjusted coefficient **
(95% Confidence Interval)
N with sufficient NRS scores over
4 weeks to calculate AUC
43 81 124
AUC (Cubic) by Week 4 Breathlessness
NRS: mean (SD)
Worst 22•86(7•12) 22•58(7•10) 22•68(7•08) 0•83 (-2•31, 2•87) 1•05 (-1•64,3•75)
Average 19•45(6•51) 19•14(6•27) 19•24(6•33) 0•79 (-2•00, 2•62) 0•81 (-1•48,3•10)
Distress* (NHI =42, NLI = 84) 16•23(7•17) 12•29(8•27) 13•60(8•11) 0•01 (0•98,6•91) 3•24 (0•25,6•23)
Cope 25•47(7.36) 27.16(6.96) 26.58(7.12) 0.20 (-4.27, 0.90) −0.87 (-3.72,1.99)
Care 31.02(8.62) 31.11(8.13) 31.08(8.27) 0.95 (-3.11,2.93) 0.25 (-2.78,3.28)
Chronic Respiratory Questionnaire -SAS
at Week 4: mean (SD)
N= 37 N= 71 N = 108
Dyspnoea domain 4•41(1•33) 4•62(1•43) 4•55(1•39) 0•47 (-0•77,0•35) −0•38 (-0•89,0•13)
Fatigue 3•36(1•05) 3•47(1•25) 3•43(1•18) 0•63 (-0•59,0•36) 0•06 (-0•40,0•51)
Emotional Function 4•59(1•08) 4•68(1•13) 4•65(1•11) 0•69 (-0•54,0•36) 0•12 (-0•26,0•51)
Mastery 4•44(1•25) 5•03(1•15) 4•83(1•21) 0•02 (-1•06,-0•11) −0•34 (-0•75,0•07)
Descriptive statistics of the primary and secondary breathlessness outcome measures, P-values and unadjusted and adjusted confidence intervals for the
difference between the two arms
SAS self administered survey (supported by research nurse); SD standard deviation; AUC area under the curve; NHI number in three sessions arm; NLI number in
one-session arm
*adjusted for baseline breathlessness intensity, gender, smoking status and age
†P-values based on student’s test with equal variance assumed
Table 4 Descriptive statistics for the summary weekly measures for repeated measures
Measure Baseline Week 4 Week 8
mean; SD (N) mean; SD (N) mean; SD (N)
Three sessions Single session Three sessions Single session Three sessions Single session
Breathlessness NRS scores
Worst 6.7 (2.0) [6] 6.9 (1.9) [12] 6.1–2.4 (37) 5.7–2.4 (70) 6.2–2.4 (25) 5.8–2.6 (56)
Average 5.4 (1.8) [6] 5.6 (1.6) [13] 5.3–2 (37) 4.9–2.3 (70) 5.2–2.2 (26) 4.8–2.3 (56)
Distress 4.7 (2.8) [7] 4.6 (3.1) [12] 4.6–2.6 (37) 4.1–3.0 (70) 3.8–2.7 (25) 3.5–3.1 (56)
Cope 6.4 (2.1) [6] 7.0 (2.1) [12] 7–2.1 (37) 7.5–1.9 (70) 7.0–2.3 (25) 7.6–2.2 (54)
Satisfaction with care 6.3 (3.4) [9] 6.5 (3.4) [20] 8.9–1.3 (37) 8.5–2.0 (70) 8.6–1.9 (25) 8.5–2.0 (55)
CIEQ-Chr
Injustice 4.5–2.7 (50) 4.2–2.6 (100) 4–2.6 (35) 3.4–2.6 (69) 3.3–2.7 (26) 3.2–2.2 (55)
Catastrophizing 5.6–3.7 (50) 4.3–3.3 (100) 4.9–3.8 (34) 3.6–3.1 (69) 4.0–3.2 (26) 3.2–3.1 (55)
Chronic Respiratory Questionnaire – SAS:
Dyspnoea domain 3.8–1.2 (51) 3.6–1.3 (103) 4–1.3 (37) 4.1–1.5 (71) 4.3–1.5 (26) 4.1–1.6 (57)
Fatigue 3–0.95 (51) 3.3–1.1 (102) 3.4–1 (37) 3.5–1.1 (71) 3.6–1.3 (26) 3.5–1.4 (57)
Emotional functioning 4.1.–1.1 (51) 4.5–1.3 (102) 4.6–1.1 (37) 4.7–1.1 (71) 4.6–1.0 (26) 4.8–1.2 (57)
Mastery 3.9–1.2 (51) 4.5–1.2 (102) 4.4–1.3 (37) 5.0–1.1 (71) 4.9–1.3 (26) 5.1–1.3 (57)
HADS score
Anxiety 7.7–4.3 (51) 6.2–4.2 (102) 7.2–3.8 (37) 5.3–4.1 (69) 6.8–4.2 (26) 5.1–4.0 (56)
Depression 6.6–3.0 (51) 6.2–3.9 (102) 5.8–3.7 (37) 5.9–3.8 (69) 5.3–3.3 (26) 5.7–4.0 (56)
KPS 72–13.5 (65) 71–9.9 (95) 71–9.0 (47) 68–12.8 (51) 73–9.6 (26) 73–8.9 (35)
HADs, Hospital anxiety and depression scale; SAS, Self-administered survey (supported by research nurse); SD, Standard deviation; N, Number; CIEQ-Chr,
Catastrophizing, injustice questionnaire in chronic disease; NRS, Numerical rating scale; KPS, Karnofsky Performance Scale
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effectiveness analysis; it is important that we can demon-
strate that the reduced clinic time for participants allocated
to the single session arm did not appear to need additional
clinic time elsewhere in the health service.
Clinical service implications
This trial provides important data to inform service pro-
viders and commissioners. A single session prevents un-
necessary burden for patients and carers and allows
services to see more patients within current resources.
Centres see hundreds of new lung cancer patients each
year, but breathlessness services only see a fraction. Access
to breathlessness clinics can be improved within current
capacity; if services who currently offer more than one ses-
sion change to a standard of single session breathing train-
ing, then more patients will receive this care.
Conclusions
There was no evidence that three sessions conferred
additional benefits over one and it was not cost-effective.
A single session therefore seems an appropriate way to
provide this service. It should not be assumed that non-
pharmacological supportive and palliative care interven-
tions are without burden and assessment of this aspect
should be incorporated in future supportive and pallia-
tive care research.
Additional file
Additional file 1: Post hoc sensitivity analysis adjusting for the
clinically significant difference in baseline CRQ mastery domain
and HADS anxiety.
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